October 27, 2017 7:23pm
As the week ended with the XBI (+2.43%) and the IBB (+0.68%) jumping
How does the song go? Know “when to hold ‘em, know when to fold ‘em”
Pre-open indications: 3 hits and 1 miss
Out and about: Cytori Therapeutics (CYTX) proposes a shareholder subscription right to purchase up to 10,000 units consisting of an aggregate of up to 10,000 Shares of Series B Preferred Stock and warrants to purchase up to 12,500,000 Shares of common stock at a price of $1,000 per unit – WHAT a JOKE! Having sought a strategic option, the same CEO who “broke” the company gets to keep his over-paid position – a BEWARE offering!
How right does one have to be? You could and should be reading this review of the day’s share pricing activity?
In the grip of rotating cycles and disparaging trends, what is the price of sector equities - knowledge and a subscription!
Friday’s results have implications to Monday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s newsletter, “headwinds remain - what I see written about more frequently are indications of ETF exposure as a number of technical indicators are weak or continue flashing warning signals. Yet, I am still of the opinion that many sector companies are oversold which says there will be a rebound but, how soon?”
After the sector got hammered through the week, it was a welcomed relief for the oversold to feel that algorithms finally “processed” that they were undervalued!
There is still a lot of skepticism i.e. sentiment but, the algorithms “set of rules” in their finite set of steps found a common divisor or factor to produce today’s multiplier.
The closer we get past fund fiscal year ends and sector quarterly results, the better the sector will be valued.
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The open was positive with an A/DL of 25/15 and 3 flats;
· The mid-day was barely positive with an A/DL of 20/19 and 4 flat;
· The close was positive with an A/DL of 29/12 and 2 flats;
Pre-open indications: 3 hit and 1 miss
- Cellectis SA (CLLS) closed up +$1.17 – miss;
- Pluristem (PSTI) closed up +$0.05 – hit;
- Regenxbio (RGNX) closed up +$0.15 – hit;
- Sangamo Therapeutics (SGMO) closed up +$0.38 – hit;
Some of MY working trend lines or indications:
… The greatest volume to the downside: MDXG, IMUC, QURE, VTGN and VCEL
… Upside volume was weighted to: SGMO, JUNO, RENE.L, XON and BLUE
… Biggest $ downside: QURE (-$0.32), VCEL (-$0.15), VTGN (-$0.12), OSIR (-$0.10) and MDXG (-$0.08)
… Largest $ upside: BLUE (+$4.20), ONCE (+$3.98), JUNO (+$2.19), CLLS (+$1.17) and XON (+$0.59)
… Flat: AGTC and AXGN
Daily analytics:
The S&P 500 and NASDAQ closed at records on Friday; equities were also buoyed by data showing the U.S. economy expanded at a solid 3% annual pace for a second straight quarter despite damages from two hurricanes, while the University of Michigan reported consumer sentiment in October was the strongest it has seen in 13 years.
· The S&P 500 SPX, +0.81% gained 20.67 points, or 0.8%, to 2,581.07.
· The Dow added 33.33 points, or 0.1%, at 23,434.19.
· The NASDAQ advanced 144.49 points, or 2.2%, to 6,701.26, for its best percentage gain since Nov. 7.
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market; Friday traded 9.80, down -13.27% …
- Thursday traded at 11.33, up +0.90% after Wednesday traded at 11.27, up +0.63% after Tuesday traded at 11.10, up +0.27% after Monday traded at 10.87, up +9.03% and last Friday traded at 9.95, down -1% …
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated:
· Friday was up +0.68%
· Thursday +0.21%
· Wednesday -0.47%
· Tuesday +0.20%
· Monday -0.74%
· Last Friday+0.46%
… The Russell 2000 (RUT) indicated
· Friday was up +0.73%
· Thursday +0.27%
· Wednesday -0.46%
· Tuesday +0.20%
· Monday -0.77%
· Last Friday +0.48%
… The iShares NASDAQ Biotechnology (IBB) indicated:
· Friday was up +0.68%
· Thursday -2.32%
· Wednesday -1.14%
· Tuesday -0.78%
· Monday -1.22%
· Last Friday -0.99%
The count - decliners versus gainers:
……. look at the differences in the spreads as decliners jump and %
· Friday’s decliners ranged from -0.30% <CYTX -$0.0013> to -12.37% <VTGN -$0.13> in 12 equities;
· Thursday’s decliners ranged from -0.25% <AXGN -$0.05> to -9.45% <CYTX -$0.049> in 27 equities;
· Wednesday’s decliners ranged from -0.23% <STML -$0.02> to -13.37% <BLFS -$0.92> in 30 equities;
· Tuesday’s decliners ranged from -0.95% <FATE -$0.04> to -8.28% <MDXG -$1.02> in 28 equities;
· Monday’s decliners ranged from -0.76% <KOOL -$0.03> to -11.37% <MDXG -$1.58> in 24 equities;
· Last Friday’s decliners ranged from -0.27% <ADRO -$0.03> to -6.67% <VCEL -$0.30> in 11 equities;
Versus
… Look at the percentage’s (%) and spreads …
· Friday’s gainers ranged from +0.30% <NWBO +$0.005> to +6.82% <FATE +$0.29> in 29 equities;
· Thursday’s gainers ranged from +0.51% <KOOL +$0.02> to +6.78% <FATE +$0.27> in 10 equities;
· Wednesday’s gainers ranged from +0.09% <NWBO +$0.0001> to +9.09% <CAPR +$0.20> in 11 equities;
· Tuesday’s gainers ranged from +0.60% <ISCO +$0.01> to +% <PSTI +$0.16> in 10 equities;
· Monday’s gainers ranged from +0.61% <ISCO +$0.01> to +11.31% <BSTG +$0.009> in 15 equities;
· Last Friday’s gainers ranged from +0.50% <AXGN +$0.10> to +27.11% <QURE +$4.11> in 28 equities;
A week’s work:
ATHX closed up +40.07 after being down -$0.04 after Wednesday’s -$0.08 after being -$0.03 after Monday’s flat at $1.99 … there are even MORE questions re their cash position going. Be ready for an offering…
CAPR closed up +$0.08 after Thursday’s -$0.08 after being up +$0.21 0n news of a presentation on 11/15 after Tuesday’s -$0.08 after Monday’s -$0.02 - CAPR can’t keep fooling investors with their brand of hype – it will run down over the next days and weeks, announcement went out too early;
CLBS closed up +$0.12 after yesterday’s -$0.08 after Wednesday’s -$0.01 after Tuesday’s -$0.11 after Monday’s -$0.10 after being flat (Friday) at $3.39 – I keep hearing stories about why they can’t get out of their own way … VTGN closed down -$0.126 after being flat at $1.02 after being down -$0.02 after Tuesday’s $1.04 after being down -$0.02– ketamine is a horse drug?;
VCEL was down -$0.15 after being up +$0.25 after being down -$0.05 after Tuesday’s -$0.10 after being up +$0.20– still believe VCEL will announce an offering … while AXGN closed flat at $20.10 after being down -$0.05 after being up +$0.15 after Tuesday’s flat at $20.00 (Tuesday and Monday) … the merry-go-round turns – I’m betting on a downside; MDXG was down -$0.08 after being up +$0.56 following being down -$1.02 post Monday’s -$1.58 on news of a profitable Q3, as I said stay in, right again;
HSGX closed down -$0.04 after Thursday’s flat at $2.17 after Wednesday’s up +$0.01 after Tuesday’s -$0.06 after Monday’s -$0.03 … I like the company i.e. still undervalued;
SGMO regain altitude +$0.38 after being down again -$0.58 after Wednesday’s -$0.75 after Tuesday’s -$0.25 post Monday’s +$0.15 while ONCE was up +$3.38 after being down -$3.35 after Wednesday’s -$1.15 after being up +$1.08 after Monday’s +$1.82 – oversold, overbought – pick the day;
BLUE was up +$4.20 after Thursday’s down -$2.85 after yesterday’s -$1.80 after Tuesday’s +$0.90 after Monday’s -$2.20 … a soccer ball score or miss;
AGTC was closed flat at $3.80 after Thursday’s flat after being down -$0.05 after being flat at $3.85 after Monday’s down -$0.20 … can’t escape the basement … is management is deaf to stockholders?
RGNX closed up +$0.15 after being down -$2.60 after being up +$0.60 after being down -$0.60 after Monday’s -$1.65 … I keep telling you to stay, right again;
Cellectis S.A. (CLLS) closed up +$1.17 after being down -$0.42 after Wednesday’s +$0.56 after Tuesday’s +$0.97 after Monday’s +$0.58 … if you stay on the merry-go-round, don’t wait for the music to stop – right again;
AST was up +$0.05 after Thursday’s +$0.05 after being down Wednesday -$0.05 after Tuesday’s -$0.15 after Monday’s -$0.10 while mothership BTX was up +$0.01 after Thursday’s +$0.02 after being -$0.12 after Tuesday’s -$0.15 after Monday’s -$0.05 … both financed to prop their balance sheets
Immuno-oncologists - JUNO closed up +$2.17 after yesterday’s +$0.47 after being down -$1.43 after yesterday’s -$0.64 after Monday’s +$1.42; as VSTM closed up +$0.21 post being down -$0-.25 after being up +$0.02 after being down again -$0.10 after Monday’s -$0.07 after Friday’s flat at $3.95 – up, down, round and round;
STML closed up +$0.48 after Thursday’s down -$0.48 after Wednesday’s -$0.02 after being -$0.18 after Monday’s -$0.10; while ADRO closed up +$0.05 post being -$0.15 after yesterday’s -$0.10 after Tuesday’s -$0.25 after Monday’s -$0.45 as BLCM closed up +$0.26 after being down -$0.57 after being flat at $10.05 after yesterday’s -$0.12 after Monday’s -$0.22 … it’s a ride with expectation in the wind;
FATE closed up +$0.29 after being up +$0.27 after being down -$0.19 after Tuesdays -$0.04 after Monday’s +$0.03 – is an offering in the near future?
MESO was down again -$0.07 after being down -$0.22 after being down -$0.52 after Tuesday’s -$0.40 post Monday’s +$0.10– still waiting for some news, as I had stated time to be accumulating on dips…
PSTI was up +$0.05 after Thursday’s -$0.06 after Wednesday’s -$0.02 after being up +$0.16 after Monday’s +$0.07 – up, down, round and round!
QURE closed down another -$0.32 after Thursday’s -$1.30 after Wednesday’s -$1.68 after yesterday’s up +$0.26 after Monday’s down -$0.75 after Friday’s +$4.11 to $19.47 following Thursday’s +$5.69 ($15.16) – an Icarus candidate (?) - An $18.25 offering was proposed on Monday, dropping the pricing?
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
